December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lundbeck

News headline image
Lundbeck Presents New VYEPTI® (eptinezumab-jjmr) and Bocunebart Migraine Data at the American Headache Society 68th Annual Scientific Meeting
From Lundbeck
Via Business Wire
News headline image
Lundbeck Presents New Data at AAN 2026 Highlighting Real-World Changes in Migraine-Related Cognitive Symptoms After Starting VYEPTI® (eptinezumab-jjmr)
From Lundbeck
Via Business Wire
News headline image
Lundbeck Collaborates with Migraine Community to Raise the Bar for Migraine Care
From Lundbeck
Via Business Wire
News headline image
Lundbeck Advances Leadership in Migraine With New Data at the American Headache Society 67th Annual Scientific Meeting
From Lundbeck
Via Business Wire
News headline image
Lundbeck to Present a Breadth of Migraine and Cluster Headache Data at the 66th Annual Scientific Meeting of the American Headache Society
From Lundbeck
Via Business Wire
News headline image
Lundbeck to Present Data on Migraine Impact Reduction and Sustained Response with VYEPTI® (eptinezumab-jjmr) at 76th Annual Meeting of the American Academy of Neurology
From Lundbeck
Via Business Wire
News headline image
Lundbeck to Present New Clinical and Real-World VYEPTI® (eptinezumab-jjmr) Data at the 65th Annual Scientific Meeting of the American Headache Society, Reinforcing Its Use in Migraine Prevention
From Lundbeck
Via Business Wire
News headline image
Lundbeck to Present Broad Range of Data on Migraine and Brain Health at 75th Annual Meeting of the American Academy of Neurology
From Lundbeck
Via Business Wire
News headline image
Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention
From Lundbeck
Via Business Wire
News headline image
Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI
From Lundbeck
Via Business Wire
News headline image
The Journal of the American Medical Association Publishes Data on Efficacy and Safety of Preventive Migraine Treatment VYEPTI® (eptinezumab-jjmr) When Administered During an Active Migraine Attack
From Lundbeck
Via Business Wire
News headline image
Lundbeck to Showcase New VYEPTI® (eptinezumab-jjmr) Data at 63rd Annual Scientific Meeting of the American Headache Society (AHS)
From Lundbeck
Via Business Wire
News headline image
New Data Presented at 2021 American Academy of Neurology (AAN) Annual Meeting Shows VYEPTI® (eptinezumab-jjmr) Demonstrated Earlier Time to Freedom from Headache Pain and Absence of Most Bothersome Symptoms Compared to Placebo When Initiated...
From Lundbeck
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.